tbuckley/cabot-search huggingface dataset:
An Appraisal of Serologic Tests for Coccidioidomycosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interleukin-10
Authors: K W Moore, A O'Garra, R de Waal Malefyt, P Vieira, T R Mosmann
Journal: Annual Review of Immunology (1993)

Interleukin-10, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/immunol/11/1/annurev.iy.11.040193.001121-1.gif
Air Pollution, Isotopes, Hepatitis Highlight Scientific Program
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What Is The Ideal Antianginal Drug?
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oncology
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Stergios Polyzos, Christos Mantzoros, Jeffrey Friedman, Heike Münzberg, Christopher Morrison, Hyeong-Kyu Park, Rexford Ahima, Neira Sáinz, Jaione Barrenetxe, María Moreno-Aliaga, José Martínez Hernández
Journal: Metabolism (2014)
Highlights
Journal: JAMA (2014)

Effect of Citalopram on Agitation in Alzheimer Disease 682Agitation is common, persistent, and difficult to treat in patients with Alzheimer disease.In a randomized trial involving 186 patients with probable Alzheimer disease and clinically significant agitation, Porsteinsson and colleagues assessed the effects of a psychosocial intervention plus either citalopram or placebo for 9 weeks.The authors report that patients who received citalopram had significantly reduced agitation and caregiver distress; however, citalopram at the target dose of 30 mg/d was associated with worsening of cognitive score and adverse cardiac effects.In an Editorial, Small discusses the treatment of agitation in patients with dementia.
Omission From “Funding/Support” Subsection of the “Acknowledgment” Section in: Functional Brain Basis of Hypnotizability
Journal: JAMA Psychiatry (2013)

Fumiko Hoeft, MD, PhD; John D. E. Gabrieli, PhD; Susan Whitfield-Gabrieli, BSc; Brian W. Haas, PhD; Roland Bammer, PhD; Vinod Menon, PhD; David Spiegel, MD
British women do not get most effective or safest test for Down's syndrome
Journal: BMJ (2001)

Low dose liposomal amphotericin B seems to be effective against visceral leishmaniasis Low dose liposomal amphotericin B given as a single dose or short five day course seems effective against visceral leishmaniasis in India.Recommended regimens of liposomal amphotericin are prohibitively expensive in developing countries, but in a pilot study on 91 patients, Sundar et al (p 419) found cure rates of 92% with a dose of 5 mg/kg given either as a single infusion or over five days.If proved effective in larger trials, low dose regimens should help make the drug more affordable.
Normal Serum Cholesterol Values
Authors: Glenn Friedman
Journal: JAMA (1973)

We determined the serum cholesterol values of 2,033 normal children, ages 2 weeks to 19 years. A test that could be performed in a physician's office was standardized and utilized. It was found that the serum cholesterol values were age-dependent. Analysis of the serum cholesterol values in the various age groups revealed that they were not statistically normally distributed. For this reason, a nomogram similar to the familiar height and weight charts for children was constructed. The nomogram permits the physician to rank a given patient with other children of his age, and to follow the changes in serum cholesterol values in a given patient as he grows older.
The Propaganda for Reform
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response
Authors: P. S. SARMA, K. J. CREMER, J. GRUBER
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response Get access PADMAN S. SARMA, PADMAN S. SARMA Biological Carcinogenesis Branch, Biological Carcinogenesis Program, Division of Cancer Etiology, National Cancer Institute, Executive Plaza North, Rm. 540, National Institutes of HealthBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar KENNETH J. CREMER, KENNETH J. CREMER Biological Carcinogenesis Branch, Biological Carcinogenesis Program, Division of Cancer Etiology, National Cancer Institute, Executive Plaza North, Rm. 540, National Institutes of HealthBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JACK GRUBER JACK GRUBER Biological Carcinogenesis Branch, Biological Carcinogenesis Program, Division of Cancer Etiology, National Cancer Institute, Executive Plaza North, Rm. 540, National Institutes of HealthBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 1, January 1989, Pages 71–72, https://doi.org/10.1093/jnci/81.1.71 Published: 01 January 1989
The availability of plasma products and the care of hemophilia patients
Authors: L. M. Aledort
Journal: JAMA (1981)

Paid plasma donor programs are being criticized, principally on the philosophical grounds that human tissue donations should be freely given and not sold. Philosophically, this argument has merit. But in reality, restricting these programs at this time would be injurious to many patients in the United States and abroad. Restrictions would be particularly damaging to the United States' hemophilia patients. Hemophiliacs fare far better today then a decade ago, thanks in large part to generous supplies of reasonably priced factor VIII and cryoprecipitate. Factor VIII is mainly supplied from commercial sources. Last year, for example, approximately 90% of the factor VIII produced in the United States came from paid sources. The widening availability of factor VIII has facilitated home treatment and preventive maintenance, freeing hemophiliacs from the time, cost, and inconvenience of repeated emergency care and hospitalization. Their new freedom has in turn freed medical and nursing staffs to develop
Research governance impediments to clinical trials: a retrospective survey
Authors: Rustam Al-Shahi Salman, Timothy M Brock, Martin S Dennis, Peter A G Sandercock, Philip M White, Charles Warlow
Journal: Journal of the Royal Society of Medicine (2007)

Objective We sought to evaluate the delays, between-centre variations in practice, and opportunity costs attributable to delays in research governance approval of clinical trials in the United Kingdom. Design Retrospective survey. Setting Research and Development (R&amp;D) departments at 50 UK National Health Service hospital trusts governing 57 hospital sites. Participants R&amp;D departments participating in four randomized multicentre clinical trials coordinated by our Neurosciences Trials Unit. Interventions None. Main outcome measures Median delay between application and research governance approval. Results Only half of the R&amp;D departments used the UK online R&amp;D form. Only a single copy of the application was required by 96% of R&amp;D departments. The median delay between application and research governance approval was 44 working days (interquartile range 23–80). A delay of &gt;20 working days was incurred by 43 applications (75%), of which 24 (56%) were not explicable and 11 (20%) were attributable to local funding negotiations. Based on the trial randomization rates at each centre, 108 patients (17% of all patients randomized) could have been randomized during the delay, at a crude cost to funding agencies of £53,743; if a four week delay was deemed acceptable, 75 patients (12% of all patients randomized) could have been randomized during unacceptable delays, at a crude cost to funding agencies of £37,700. Conclusions The UK research governance system incurs unacceptably long and costly delays for clinical trials. Urgent reform is needed, including rapid design and uniform implementation of the ‘bureaucracy busting’ measures in Best Research for Best Health
Oxygen Radicals and Asbestos Carcinogenesis
Authors: Valerie D. Moyer, Cheryl A. Cistulli, Charles A. Vaslet, Agnes B. Kane
Journal: Environmental Health Perspectives (1994)

Asbestos fibers have been shown to generate reactive oxygen species using a variety of in vitro assays.It is hypothesized that these highly reactive metabolites mediate the development of malignant mesothelioma induced by asbestos fibers.DNA is a potential target of oxidant attack.Adaptive responses to oxidant injury have been described during exposure of mesothelial cells to asbestos fibers in vitro.Failure of these adaptive responses may lead to genetic instability and alterations in oncogenes and tumor suppressor genes that confer a proliferative advantage to emerging neoplastic mesothelial cells.-
International Symposium of the Society of Toxicologic Pathologists
Journal: JNCI Journal of the National Cancer Institute (1981)

International Symposium of the Society of Toxicologic Pathologists Get access JNCI: Journal of the National Cancer Institute, Volume 67, Issue 5, November 1981, Page 1178, https://doi.org/10.1093/jnci/67.5.1178-a Published: 01 November 1981
Metaplasia
Authors: Tolulope Kehinde
Journal: Annals of Internal Medicine (2016)

Ad Libitum17 May 2016MetaplasiaTolulope Kehinde, BATolulope Kehinde, BAFrom Geisel School of Medicine at Dartmouth College, West Lebanon, New Hampshire.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-0568 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I am to become youWith your fifty dollar wordsAnd eccentric phrases.Obnubilated is to replace confused,Red bruise to become erythematous ecchymosis.In the right person, a wince at my handshakeCan no longer be just that.Perhaps Rheumatoid arthritis?A shuffling gait is no longer lazinessLike my father used to tell me.Maybe my elderly neighbor has Parkinson's.As ... Author, Article, and Disclosure InformationAffiliations: From Geisel School of Medicine at Dartmouth College, West Lebanon, New Hampshire.Current Author Address: Tolulope Kehinde, BA; e-mail, tkehinde.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 May 2016Volume 164, Issue 10Page: 704KeywordsBrainElderlyRheumatoid arthritis ePublished: 17 May 2016 Issue Published: 17 May 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Panniculitis and systemic lupus erythematosus
Authors: R. K. Winkelmann
Journal: JAMA (1970)

Three cases of systemic lupus erythematosus and panniculitis illustrate the inflammatory, sclerotic, and ulcerative clinical features of the skin lesions. Histopathologic diagnosis is characterized by poikiloderma, lymphocytic inflammation, hyaline necrosis of collagen and fat, and focal calcification. The lesions respond to antimalarial and corticosteroid therapy, and full-thickness skin grafts are well tolerated. The differential diagnosis includes other forms of panniculitis and localized scleroderma.
Aspects of depression associated with borderline personality disorder
Authors: J H Rogers, T A Widiger, A Krupp
Journal: American Journal of Psychiatry (1995)

Shared symptoms between borderline personality disorder and depression have resulted in inherent difficulties in evaluating the relationship between these disorders. Some theorists have argued that depression in patients with borderline personality disorder is qualitatively distinct from depression in nonborderline patients. The purpose of this study was to empirically identify aspects of depression most associated with borderline personality disorder.Through interview and self-report measures, the authors studied depression in 50 inpatients, 21 of whom had borderline personality disorder.The aspects of depression most associated with borderline personality disorder were self-condemnation, emptiness, abandonment fears, self-destructiveness, and hopelessness; boredom and somatic complaints exhibited no association.Depression associated with borderline pathology appears to be in some respects unique, as well as distinct from nonborderline depression. The study's implications delineate the importance of considering the phenomenological aspects of depression in borderline personality disorder.
Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials
Authors: J. Q. Huang, G. F. Zheng, R. Deuson, Y. Briand, G. C. F. Chan, J. Karlberg, B. C. Y. Wong
Journal: Journal of Clinical Oncology (2004)

6037 Background: 5-HT3 receptor antagonists combined with dexamethasone are commonly used to control delayed CINV, despite the lack of supporting evidence from randomized clinical trials. We aimed to evaluate systematically if adding a 5-HT3 receptor antagonist to dexamethasone (combination therapy) is more effective than dexamethasone alone for preventing delayed CINV. Methods: We undertook a meta-analysis of studies that met the following criteria: randomized clinical trials comparing the efficacy of the combination therapy versus dexamethasone alone for preventing delayed CINV; same prophylactic treatment for acute CINV must be used. Studies without raw data or duplicate publications were excluded. A comprehensive literature search was conducted to October 2003 in Medline, PubMed, Embase, CANCERLIT and Cochrane Databases, supplemented by a hand search of reference lists, relevant meeting abstracts and journals. Results: Of 50 potentially useful studies, 5 reports involving 1997 patients that met the predefined entry criteria were included. The overall total protection (no nausea, no vomiting, any / or without rescue medications) from delayed CINV was similar between patients receiving the combination therapy (53.2%, 454/853) and dexamethasone alone (53.3%, 450/844), yielding a relative risk (RR) of 1.03 [95% confidence interval (CI) 0.97–1.09]. Similar efficacy between the two treatment groups was also observed for preventing delayed nausea [RR 1.03 (95% CI 0.98–1.09)] and delayed vomiting [RR 1.03 (95% CI 0.99–1.07)]. Conclusions: Adding a 5-HT3 receptor antagonist to dexamethasone does not improve the antiemetic effect of dexamethasone for preventing delayed CINV. The current recommendation of using this combination treatment for controlling delayed CINV warrants evidence-based re-evaluation. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck & Co., Inc.; Merck, Sharpe & Dohme, France Merck & Co. Inc
AGRANULOCYTIC ANGINA
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PHYSICIANS HONORARIUM IN PRESIDENT McKINLEY'S CASE.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hemotropic Bacteria
Authors: Miodrag Ristic, Julius P. Kreier
Journal: New England Journal of Medicine (1979)

Bacterial-type organisms that adhere to erythrocytes and produce severe diseases of economic importance in domestic and wild animals have been recognized since the turn of the century.1 2 3 In contrast, physicians in general have not encountered hemotropic bacteria except Bartonella bacilliformis, which causes Oroya fever and verruga peruana. This organism is limited to a small ecosphere in the Andes.4 The disease described by Archer and his colleagues in this issue and the cases earlier reported by Kallick et al.5 may bring about a new awareness of hemotropic bacteria as a hazard to human health.An interesting feature of the disease . . .